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Changes in the Incidence of Candidiasis in Neonatal
Intensive Care Units
WHAT’S KNOWN ON THIS SUBJECT: The incidence of invasive
candidiasis in hospitalized infants is related to postnatal
exposures, but large-scale studies relating the incidence of
invasive candidiasis to changes in exposures over time are not
available.
WHAT THIS STUDY ADDS: This study describes the association
between the incidence of invasive candidiasis and changes in use
of antifungal prophylaxis, empirical antifungal therapy, and broad-
spectrum antibacterial antibiotics over time.
abstract
OBJECTIVE: Neonatal invasive candidiasis is associated with significant
morbidity and mortality. We describe the association between invasive
candidiasis and changes in use of antifungal prophylaxis, empirical anti-
fungal therapy, and broad-spectrum antibacterial antibiotics over time.
METHODS: We examined data from 709 325 infants at 322 NICUs man-
aged by the Pediatrix Medical Group from 1997 to 2010. We deter-
mined the cumulative incidence of invasive candidiasis and use of
antifungal prophylaxis, broad-spectrum antibacterial antibiotics, and
empirical antifungal therapy by year.
RESULTS: We identified 2063 (0.3%) infants with 2101 episodes of in-
vasive candidiasis. Over the study period, the annual incidence of in-
vasive candidiasis decreased from 3.6 episodes per 1000 patients to 1.4
episodes per 1000 patients among all infants, from 24.2 to 11.6 epi-
sodes per 1000 patients among infants with a birth weight of 750–
999 g, and from 82.7 to 23.8 episodes per 1000 patients among infants
with a birth weight ,750 g. Fluconazole prophylaxis use increased
among all infants with a birth weight ,1000 g (or ,1500 g), with the
largest effect on birth weights ,750 g, increasing from 3.8 per 1000
patients in 1997 to 110.6 per 1000 patients in 2010. The use of broad-
spectrum antibacterial antibiotics decreased among all infants from
275.7 per 1000 patients in 1997 to 48.5 per 1000 patients in 2010. The
use of empirical antifungal therapy increased over time from 4.0 per
1000 patients in 1997 to 11.5 per 1000 patients in 2010.
CONCLUSIONS: The incidence of invasive candidiasis in the NICU de-
creased over the 14-year study period. Increased use of fluconazole
prophylaxis and empirical antifungal therapy, along with decreased
use of broad-spectrum antibacterial antibiotics, may have contributed
to this observation. Pediatrics 2014;133:236–242
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Invasive candidiasis is an important
cause of sepsis in the NICU. Candida
infections in infants are associated
with significant mortality and morbidity,
including neurodevelopmental impair-
ment, among survivors.1–3 The incidence
of invasive candidiasis ranges from 2.6%
to 13.2% in very low birth weight infants
(,1500 g) and from 6.6% to 26.0% in
extremely low birth weight (ELBW)
infants (,1000 g).1–11
Previously identified risk factors for
invasive candidiasis in the NICU include
lowbirthweight, prematurity, presence
of central catheters, days ofmechanical
ventilation, abdominal surgery, and
exposure to broad-spectrum antibac-
terial antibiotics (eg, third-generation
cephalosporins).1,11,12 The incidence of
invasive candidiasis varies significantly
by center.1,3,13 Variation in the incidence
of invasive candidiasis and its associa-
tion with poor outcomes should prompt
evaluation of how changes or differences
in clinical practices might influence the
risk of acquiring this disease.
Invasive candidiasis inhospitalized infants
appears to be decreasing. We hypothe-
sized that increased use of antifungal
prophylaxis and empirical antifungal
therapy as well as avoidance of broad-
spectrum antibacterial antibiotics may
explain thedecreasing incidence. Herein,
we use a large multicenter cohort to
describe the incidence of candidiasis in
the NICU and parallel changes in the use
of antifungal prophylaxis, broad-spectrum
antibacterial antibiotics, and empirical
antifungal therapy overa 14-yearperiod.
METHODS
We examined a cohort of all infants
discharged from322NICUsmanagedby
the Pediatrix Medical Group from 1997
to 2010. Data were collected pro-
spectively from daily progress notes
generated by clinicians. We determined
the cumulative incidence of invasive
candidiasis and the use of antifungal
prophylaxis,broad-spectrumantibacterial




by using standard-of-care practices at
each NICU. We defined invasive candidi-
asis as the presence of a positive culture
(blood, urine, cerebrospinal fluid, or a
combination of these). Urine cultures
were included only if obtained via in-and-
outcatheterizedorsuprapubicaspiration.
Multiple positive cultures for Candida
within 21 days were considered a sin-
gle episode of infection.
We defined antifungal prophylaxis as
a combination of the following: (1) an-
tifungal started in the first 5 postnatal
days, (2) course of treatment lasting
.7 days, and (3) no positive Candida
culture before or on the day the anti-
fungal prophylaxis was started. We
defined empirical antifungal therapy
as a combination of the following: (1)
presence of a culture obtained while
the patient was receiving antifungal
therapy, (2) no positive Candida cul-
tures within the previous 14 days, and
(3) excluding therapy defined as anti-
fungal prophylaxis. We defined the
administration of a broad-spectrum
antibacterial antibiotic as exposure to
a third-generation cephalosporin or
carbapenem at any time during the
NICU hospitalization.
Statistical Analysis
We organized our data in 3 separate
ways: at the national level for each year,
at the site level for each year, and at the
culture level for each patient. At the
nationalandsite levels, foreachyearwe
calculated the incidence (episodes per
1000 patients) of invasive candidiasis.
We also calculated the use (per 1000
patients)of antifungalprophylaxis, broad-
spectrum antibacterial antibiotics, and
empirical antifungal therapy. Both na-
tionally and by site, the annual incidence
ofcandidiasis,useofantifungalprophylaxis,
use of broad-spectrum antibacterial anti-
biotics, and use of empirical antifungal
therapy were calculated for all infants
in our sample, as well as for those in
each of 4 birth weight groups:$1500 g,
1000–1499 g, 750–999 g, and ,750 g.
To examine the association between
broad-spectrum antibacterial antibiotic
use and the incidence of invasive can-
didiasis at the site level, we accounted
for 2 key aspects of the data. In many
cases, especially among heavier infants,
the incidence of invasive candidiasis at
a site was 0. In addition, the number of
observationsvariedsubstantiallyacross
sites over time. We used Tobit models to
account for the censoring of the data at
0 and weighted the observations by the
number of patients at each site in each
year toaccount fordifferences insample
size across sites.14
Weusedmultivariable logistic regression
to examine the relationship between ex-
posure to broad-spectrum antibacterial
antibiotics in the 7 days before a culture
and the development of invasive candi-
diasis, controlling forgestationalage. The
unit of observation for this analysis was
the culture. Because cultures were
obtained on widely varying days of life
across infants, we used conditional lo-
gistic regression in which infants were
stratified according to the postnatal day
the culture was obtained.12 All analyses
were performed by using Stata 12.0
(StataCorp, College Station, TX). The Duke
University Institutional Review Board and
the Western Institutional Review Board
approved this study.
RESULTS
We included 709 325 infants in the final
analysis. A total of 2063 (0.3%) infants
had 2101 episodes of invasive candidi-
asis. The median gestational age of
infants with invasive candidiasis was
26 weeks (interquartile range: 24–29
weeks) compared with 35 weeks (33–
38 weeks) for those without invasive
candidiasis (P , .001) (Table 1). The
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median birth weight for infants with
invasive candidiasis was 791 g (640–
1193 g) compared with 2486 g (1825–
3200 g) for those without invasive
candidiasis (P , .001). Mortality was
higher for infants with invasive candi-
diasis (19.9% vs 2.1%; P , .001). Over
the 14-year period, the annual incidence
of invasive candidiasis decreased from
3.6 per 1000 infants to 1.4 per 1000
infants, with the greatest decrease
among infants with a birth weight
,750 g (82.7 to 23.8 per 1000 infants)
and infants with a birth weight of 750–
999 g (24.2 to 11.6 per 1000 infants)
(Fig 1). The incidence of invasive can-
didiasis decreased beginning in 2001
and continued to decrease through the
remainder of the study period.
We identified 2831 (0.4%) infants who
received antifungal prophylaxis. Flucon-
azole was the antifungal drug most
frequently used for prophylaxis (n =
2625, 92.7%). We observed increasing
use of fluconazole antifungal prophylaxis
beginning in 2002 (Fig 2). Over the study
period, the use of fluconazole for anti-
fungal prophylaxis increased among all
infants from 0.1 per 1000 patients to 7.4
per 1000 patients. The greatest increase
was observed among infantswith a birth
weight,750 g, from3.8 to 110.6 per 1000
patients.
We identified 7494 (1.1%) infants who
received $1 courses of empirical an-
tifungal therapy, including 1417 infants
who received$2 courses. The median
duration of empirical courses was 8
days (4, 14 IQR). Empirical treatment
included 3959 courses of amphotericin
products and 4209 courses of flucona-
zole. Among infants who received em-
pirical antifungal therapy, 599 (8.0%)
developed invasive candidiasis while
receiving therapy. Over the study period,
we observed an increase in empirical
antifungal therapy among all infants,
from 4.0 per 1000 patients in 1997 to
11.5 per 1000 patients in 2010. We ob-
served the greatest increase among
infants with birth weight ,750 g, from
67.7 to 206.0 per 1000 patients.
Over the study period, the use of broad-
spectrum antibiotics decreased among
all infants from 275.7 to 48.5 per 1000
patients (Fig 3). Exposure to broad-
spectrum antibacterial antibiotics was
associated with an increased risk of
invasive candidiasis (adjusted odds ratio
[OR]: 1.88; 95% confidence interval [CI]:
1.72–2.07; c statistic = 0.87). This find-
ing was broadly mirrored at the level of
different sites. Among the 3 smaller
birth weight groups (1000–1499 g, 750–
999 g, and,750 g), each 10% decrease
in the incidence of broad-spectrum
antibacterial antibiotic use was asso-
ciated with a 2.9% to 7.3% decrease in
TABLE 1 Demographic Characteristics
Invasive Candida Infection No Invasive Candida Infection
N 2063 707 262
Gestational age, %
,26 weeks 48.0 2.9
26–28 weeks 26.0 5.2
29–33 weeks 15.1 22.2
34–36 weeks 5.3 29.8
$37 weeks 5.6 40.0
Birth weight, %
,750 g 43.5 2.8
750–999 g 24.2 3.5
1000–1499 g 15.4 9.2
$1500 g 16.9 84.5
Race/ethnicity, %
White 40.3 53.9









Inborn, % 75.0 85.1
Died, % 19.9 2.1
Antenatal steroid use, % 66.1 34.1
Cesarean delivery, % 50.7 54.9
FIGURE 1
Candidiasis by year and birth weight.
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the incidence of invasive candidiasis
(Table 2). There was no significant as-
sociation between broad-spectrum
antibacterial antibiotic use and in-
vasive candidiasis among infants with
a birth weight of $1500 g (P = .18).
DISCUSSION
In this large cohort of hospitalized
infants we observed a decrease in the
incidence of invasive candidiasis over
the study period. We observed the
largest decrease among infants with
birth weights of,750 g and 750–999 g.
During this same time period, we also
observed an increased use of antifungal
prophylaxis and empirical antifungal
therapy, as well as decreased use of
broad-spectrum antibacterial antibiotics.
These changes in clinical practice may
have contributed to the decreased in-
cidence of invasive neonatal candidiasis.
The decreasing incidence of invasive
candidiasis found in this study is sim-
ilar to previously published data from
130 523 infants admitted to 128 NICUs
participating in the National Nosoco-
mial Infections Surveillance System.13
Data from the system revealed a small
decrease in the incidence of Candida
bloodstream infection in infants with
a birth weight ,1000 g, from 6.6% in
1995–1999 to 5.1% in 2000–2004.13 Our
data reveal further decreases in in-
vasive candidiasis among infants
,1000 g after 2004. Changes in neonatal
clinical practice are at least partially
responsible for the decreasing trend of
invasive candidiasis. These changes in
practice, including increased use of
antifungal prophylaxis and decreased
use of broad-spectrum antibacterial
antibiotics, are supported by findings
from randomized clinical trials and
observational studies. A meta-analysis
of 656 infants from 5 randomized trials
found that fluconazole antifungal pro-
phylaxis in high-risk infants reduces
the incidence of invasive candidiasis in
very low birth weight infants by 52%
(number needed to treat = 11; 95% CI:
7–33).8,9,15 Results from the first ran-
domized controlled trials of flucona-
zole prophylaxis published in 2001 and
the first Cochrane review published in
2004 likely influenced practice in NICUs
in our data set.5,9,16 Our findings sug-
gest that providers are administering
antifungal prophylaxis according to the
most common recommendations that
prophylaxis should target infants with
birth weights ,1000 g, although the
majority of infants with a birth weight
,1000 g are not exposed to antifungal
prophylaxis.17,18
Previous studies support an associa-
tion between invasive Candida infec-
tions and exposure to broad-spectrum
antibacterial antibiotics.2,11,12,19 Broad-
spectrum antibacterial antibiotic ex-
posure in a cohort of 3702 ELBW infants
was associated with invasive candidi-
asis (OR: 2.16; 95% CI: 1.42–3.27).11
Similarly, we observed an association
between broad-spectrum antibacterial
antibiotics and increased risk of in-
vasive candidiasis at the culture level
(OR: 1.88; 95% CI: 1.72–2.07). In our co-
hort, use of broad-spectrum antibac-
terial antibiotics decreased over time,
mirroring the decrease in invasive
candidiasis. Indeed, the Tobit regression
FIGURE 2
Fluconazole prophylaxis by year and birth weight.
FIGURE 3
Broad-spectrum antibacterial antibiotic use by year and birth weight.
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results imply that, on average, sites that
reduced broad-spectrum antibiotic use
the most had the largest decrease in
candidiasis.
Many ELBW infants are exposed to
empirical courses of antifungal agents
for suspected fungal sepsis. The in-
creased use of empirical antifungal
therapy observed during the study pe-
riod likely reflects an increased aware-
ness of the need for early therapeutic
intervention for improvedoutcome from
Candida sepsis and of the association
between invasive candidiasis and mor-
tality and neurodevelopmental impair-
ment in this high-risk population. The
diagnosis of invasive candidiasis is
made difficult by the nonspecific clinical
presentation of the disease and low
sensitivity of current microbiologic di-
agnostic techniques.17 Widespread use
of empirical antifungal therapy could
potentially contribute to a reduction in
the incidence of invasive candidiasis by
decreasing or eliminating fungal colo-
nization. The effect of empirical anti-
fungal therapy on outcomes will likely
bemore significant if treatment courses
target infants at higher risk of fungal
sepsis.3,12,20
Weacknowledge thatotherunmeasured
practice changes could contribute to
the decrease in invasive candidiasis. A
growing number of NICU quality im-
provement initiatives targeting central
catheter management and designed
to decrease central line–associated
bloodstream infections may have con-
tributed to our findings. From 1999 to
2009, data from the National Nosoco-
mial Infections Surveillance System
and the National Healthcare Safety
Network revealed that the overall
incidence of central line–associated
bloodstream infections due to Candida
spp. decreased from 0.92 to 0.2 per
1000 central line days.21 Hand-washing
has been identified as an important
practice to decrease hospital-acquired
infections.22,23 The introduction of cen-
tral catheter management bundles and
hand-washing compliance was not
measured but may have contributed to
the reduction in invasive candidiasis.
However, the incidence of bacteremia
remained stable at 30 per 1000 infants
in the years 1997–2001 versus 32 per
1000 infants from 2006 to 2010. Anti-
fungal treatment of neonatal candidi-
asis has also changed over the past
decade, with higher dosing recom-
mendations for fluconazole therapy
and the introduction of newer antifun-
gal agents, such as the class of echi-
nocandins.24–28 Decreased exposure to
other risk factors might also explain
the decreased incidence of candidiasis.
For example, overall histamine-2 blocker
use decreased from 66 per 1000 infants
in the years before the decrease in
candidiasis (1997–2001) to 52 per 1000
infants later in the study period (2006–
2010). Similarly, exposure to mechanical
ventilation decreased from 280 to 229
per 1000 infants.
The decline in the incidence of invasive
candidiasis has a profound effect on
required sample size for well-powered
trials to evaluate the efficacy of anti-
fungal agents for both prophylaxis and
treatment. For example, fluconazole
prophylaxis results in a relative risk
reduction in the incidence of invasive
candidiasisofbetween50%and80%.15,29
The sample size required to observe
this difference in the context of a clini-
cal trial is now dramatically higher,
given the decrease in the incidence of
neonatal candidiasis. The decrease in
the incidence of invasive candidiasis
will also have a large impact on en-
rollment in antifungal efficacy trials.
Most moderately sized NICUs admit
∼500 infants per year. We estimate
that, given difficulties obtaining pa-
rental consent, exposure of infected
infants to previous empirical antifun-
gal agents, and exclusion criteria, only
one-third of infected infants could be
enrolled in a randomized efficacy trial.
Given a cumulative incidence of 1.4
infections per 1000 infants, a 250-infant
study would require 10 years and 100
NICUs to complete enrollment.
Strengths of this study include the
large number of infants in the analysis,
particularly a significant proportion of
hospitalized ELBW infants from across
the United States. Given that the ma-
jority of episodes of neonatal invasive
candidiasis occur in ELBW infants and
in the NICU setting, our findings are
likely representative of the actual bur-
den of disease in this population. This
study provides evidence for an overall
downward trendof invasive candidiasis
in the NICU population across the
country. Of course, not all individual
units may have experienced the same
degree of change. Given the retro-
spectivenatureof thesedata,wearenot
able to examine causal relationships
between changes in all clinical practi-
ces and the reduced incidence of in-
vasive candidiasis. It is also possible
that later use of fluconazole (after the
first 5days)was targetedprophylaxis in
infants being treated with prolonged
antibiotics or that necrotizing entero-
colitis was included in the empirical
antifungal category. We also acknowl-
edge the possibility that other changes
in clinical care, such as changes in
ventilator management, central line
TABLE 2 Effect of a 10% Decrease in Antibiotic Use on Incidence of Candidiasis (Tobit
Regressions)
Birth Weight, g Decrease in Candidiasis, per 1000 Infants Decrease in Candidiasis, % P
,750 3.0 7.3 ,.001
750–999 1.3 5.7 ,.001
1000–1499 0.2 2.9 ,.001
$1500 ,0.1 0.4 .18
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care, and feeding practices, may have
influenced the riskof acquiring invasive
candidiasis. For example, although in-
vasive candidiasis began to decrease in
2001, the increase in antifungal pro-
phylaxis did not begin until 2002.
CONCLUSIONS
Our findings show a substantial de-
crease in the incidence of invasive
candidiasis in the NICU setting. This
decrease was likely the result of pro-
gressive changes in neonatal clinical
practice. The decreased incidence of
invasive candidiasis will likely not only
reduce overall health care costs but
also improve neonatal outcomes. Each
NICU should closely monitor its in-
cidenceof invasive candidiasis because
low rates are achievable. Similar to
preventing central line–associated
bloodstream infections and group B
Streptococcus, we want to eliminate
these infections. Additional clinical tri-
als addressing the efficacy of antifungal
prophylaxis and empirical antifungal
therapy may not be feasible given the
current incidence of the disease. A
comparison of practices between NICUs
with high and low rates of candidiasis
may be helpful in providing further evi-
dence for best practices in the pre-
vention of this disease.
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